ArticleScientific reports2025
Discovery and structural characterization of newly identified mutations in the HBx gene of chronic HBV patients.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined C-terminal truncation and point mutations in HBx in genotype D1 HBV-associated hepatocellular carcinoma.Infectious agents and cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HBV infection remains a major cause of chronic liver disease and hepatocellular carcinoma worldwide. HBx is a key regulatory protein involved in viral persistence and host-virus interactions, yet its sequence variability in Middle Eastern populations remains insufficiently characterized. In this study, the HBx region was screened in 50 Iranian patients with chronic HBV infection, and four representative samples with distinct HRM profiles were selected for sequencing. Several newly identified substitutions were detected, including two glycine substitutions (G37A and G73V) and one proline substitution (P32H), while G43D corresponded to a previously reported variant. Among these, Gly73 variants were recurrent across multiple samples. Qualitative structural modeling of full-length HBx suggested that these substitutions may contribute to subtle local conformational changes near regulatory regions; however, these observations remain preliminary and require experimental validation. Clinical and biochemical parameters showed heterogeneous patterns across cases, with Gly73 variants detected in patients with higher viral loads, although no statistically significant associations were observed due to the small sample size. All sequences belonged to genotype D. Overall, this exploratory analysis expands the existing catalog of HBx variability in a Middle Eastern cohort and highlights several newly identified substitutions that warrant further investigation in larger functional studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.